Clinical Trial Detail

NCT ID NCT03628209
Title Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

osteosarcoma

Therapies

Azacitidine + Nivolumab

Age Groups:

No variant requirements are available.